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BACKGROUND/OBJECTIVES: Subjects with type-2 diabetes are typically obese with dysfunctional adipose tissue (AT). Glucagon-
like peptide-1 (GLP-1) analogues are routinely used to improve glycaemia. Although, they also aid weight loss that improves AT
function, their direct effect on AT function is unclear. To explore GLP-1 analogues’ inﬂuence on human AT’s cytokine and
extracellular matrix (ECM) regulation, we therefore obtained and treated omental (OMAT) and subcutaneous (SCAT) AT samples
with Exendin-4, an agonist of the GLP-1 receptor (GLP-1R).
SUBJECTS/METHODS: OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon &
Exeter Hospital (UK) were treated with increasing doses of Exendin-4. Changes in RNA expression of adipokines, inﬂammatory
cytokines, ECM components and their regulators were assessed and protein secretion analysed by ELISA. GLP-1R protein
accumulation was compared in paired AT depot samples.
RESULTS: Exendin-4 induced an increase in OMAT adiponectin (P= 0.02) and decrease in elastin expression (P= 0.03) in parallel
with reduced elastin secretion (P= 0.04). In contrast to OMAT, we did not observe an effect on SCAT. There was no change in the
expression of inﬂammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF. GLP-1R accumulation was higher in SCAT.
CONCLUSIONS: Independently of weight loss, which may bias ﬁndings of in vivo studies, GLP-1 analogues modify human OMAT
physiology favourably by increasing the insulin-sensitising cytokine adiponectin. However, the reduction of elastin and no apparent
effect on AT’s inﬂammatory cytokines suggest that GLP-1 analogues may be less beneﬁcial to AT function, especially if there is no
associated weight loss.
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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced
by the intestinal L-cells from a post-translational processing of
proglucagon.1 GLP-1 secretion is enhanced in response to nutrient
ingestion and leads to a glucose-dependent increase of insulin
release, which contributes to improved glucose homoeostasis.
GLP-1 modulates satiety and reduces gastric emptying typically
with a net effect of weight loss. GLP-1 has a short half-life owing to
its rapid enzymatic degradation by dipeptidyl peptidase-4. Several
analogues resistant to dipeptidyl peptidase-4 are routinely used
for type-2 diabetes treatment. The concomitant weight loss also
observed in non-diabetic patients led to consideration of GLP-1
analogues for obesity care.2
Adipose tissue (AT) is a connective tissue in which cells are
embedded in a dense extracellular matrix (ECM) composed of
structural proteins (collagens, elastin) and adhesion proteins
(ﬁbronectin, proteoglycans and so on), which ensure its mechan-
ical stability, strength and elasticity.3 Obesity is associated with
profound remodelling of AT’s ECM that can lead to the establish-
ment of ﬁbrosis.4 Together with chronic inﬂammation, macro-
phage inﬁltration and adipocyte hypertrophy, these changes
characterise AT dysfunction of obesity and insulin resistance. It is
well established that inﬂammation as one of the key features of AT
dysfunction improves with weight loss,5 whereas direct GLP-1
effects on human AT physiology are poorly deﬁned and difﬁcult to
distinguish, in vivo, from GLP-1-induced weight loss and related
improvement in glucose control as result of its incretin effect. Its
receptor, GLP-1 receptor (GLP-1R), is expressed in human AT,
especially by cells of the stromal vascular fraction but also by
adipocytes,6 suggesting a role for GLP-1 on AT. Beneﬁcial effects
of GLP-1 were reported on modulation of ECM remodelling in
mice myocardium showing that Exendin-4 may be able to protect
from post-myocardial infarction associated interstitial ﬁbrosis
by limiting inﬂammation and reducing transforming growth
factor β3 (TGFβ3) and collagen expression,7 however, the direct
effects of GLP-1 on AT, especially in view of inﬂammation and ECM
remodelling have not yet been examined.
In order to understand whether GLP-1 analogues improve AT
dysfunction independent of weight loss and, especially as not all
patients treated with GLP-1 analogues lose weight, the present
study aims to evaluate potential effects of Exendin-4, a GLP-1
analogue, on human AT physiology in omental (OMAT) and
subcutaneous AT (SCAT) explants.
MATERIALS AND METHODS
AT collection
OMAT and SCAT biopsies were obtained with consent from participants
undergoing elective abdominal surgery at the Royal Devon & Exeter
Hospital with ethics permission granted by the Royal Devon & Exeter
Tissue Bank Steering Committee of the Exeter NIHR Clinical Research
Facility (Exeter, UK). AT samples for explant culture were collected from
seven non-diabetic overweight women with full ethical consent (seven
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subcutaneous abdominal with six paired OMAT biopsies). In brief, the
patient characteristics of each group from this cohort were: OMAT
(mean± s.d.): n=6, age 60.2 ± 11.2 years, BMI 29.0 ± 6.9 kg m− 2, subcuta-
neous: n= 7, age 60.7 ± 10.3 years, BMI 28.4 ± 6.5 kg m− 2. AT samples used
for protein extraction were paired OMAT and SCAT biopsies collected from
eight women of which ﬁve were diagnosed with diabetes; age 51.4 ± 6.5
years, BMI 44.6 ± 7.8 kg m− 2. Subjects with acute or chronic inﬂammatory
disease, those that had undergone steroid treatment in the last 3 months
or had recently taken part in a weight loss intervention/surgery were
excluded.
AT explant culture
AT was collected in Hank's Balanced Salt Solution (PAA laboratories, Pasching,
Austria) supplemented with 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid (Gibco, Life Technologies, Paisley, UK), 0.1% Gentamicin, 1%
Amphotericin (both from Sigma-Aldrich, St Louis, MO, USA). Tissue was
dissected into 5–10 mg pieces, removing blood vessels and connective
tissue. Approximately 250 mg of tissue was cultured in Media 199 (Gibco, Life
Technologies), supplemented with 5% fetal calf serum and 1% penicillin/
streptomycin) with increasing concentrations of Exendin-4 (Isca Biochemicals,
Exeter, UK), a dipeptidyl peptidase-4-resistant GLP-1R agonist sharing 53%
structural homology with GLP-1.8 Tissue explants were incubated at 37 °C for
45 h in an atmosphere of 5% CO2. Media was used for analysis of protein
secretion by ELISA and tissue frozen in Tri Reagent solution (Ambion, Life
Technologies) for further RNA processing.
RNA extraction
RNA was extracted using TRI Reagent according to the manufacturer’s
protocol. Isolated RNA was treated with DNase I (Thermo Scientiﬁc, Paisley,
UK) and converted to complementary DNA using the SuperScript VILO
cDNA Synthesis Kit (Invitrogen, Life Technologies) as previously described.9
Gene expression analysis
Gene expression analysis was carried out using Taqman Low-Density Array
cards (Life Technologies) on an ABI7900HT instrument (Applied Biosys-
tems, Life Technologies). Relative gene expression was determined using
the ΔΔCT method, with expression levels normalised to the geometric
mean of three housekeeping genes (GAPDH, PPIA and UBC). TaqMan
probes used are listed in Supplementary Table 1. All samples were
ampliﬁed in duplicate and data are presented as arbitrary units.
Western blot
Tissue samples were homogenised in radioimmunoprecipitation assay buffer
as previously described.10 Total protein (30 μg) was separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis. Primary antibodies used
were GLP-1 R (1:500, ab186051, Abcam, Cambridge, UK) and β-actin (1:1000,
A5441, Sigma-Aldrich, Gillingham, UK). Infrared ﬂuorescent signals were
detected with relevant secondary antibodies (Li-Cor, Lincoln, NE, USA) using
an Odyssey CLx and quantiﬁed with Image studio (Li-Cor).
ELISA
Protein release in supernatant was evaluated using ELISA kits: total
adiponectin, monocyte chemoattractant protein-1 (MCP-1) (both from Life
Technologies) and elastin (Cloud-Clone Corp., Caltag MedSystems Ltd,
Buckingham, UK). Samples were run in duplicate and absorbance
measured at 450nm wavelength using a PHERAstar FS (BMG Labtech,
Aylesbury, UK) microplate reader.
Statistical analysis
All data are presented as the mean± s.e.m. unless otherwise stated.
Assessment of the dose response of Exendin-4 was analysed using
Friedman’s one-way analysis of variance followed by a Dunn’s post hoc test
to correct for multiple testing. For western blot analysis, statistical
signiﬁcance was assessed using a Wilcoxon test. Statistics were performed
using GraphPad Prism 5.04 software (La Jolla, CA, USA), P-valueso0.05
were considered signiﬁcant.
RESULTS
In the following sections, we studied the effect of GLP-1R agonists
on human OMAT and SCAT by studying the dose response to
Exendin-4 treatment ex vivo.
Adipokines
Adiponectin (ADIPOQ) exerts cardioprotective, insulin-sensitising
and anti-inﬂammatory effects.11 AT explant treatment with
Exendin-4 increased ADIPOQ expression in OMAT (Figure 1a and
Table 1) with no effect in SCAT (Table 1). To conﬁrm this
observation, we measured adiponectin levels in supernatant
obtained from explant culture. We did not observe any modiﬁca-
tion of adiponectin secretion in OMAT or SCAT (Figure 1b). Leptin
is involved in the regulation of satiety, energy expenditure, body
weight and insulin sensitivity.11 LEP expression was not signiﬁ-
cantly altered by Exendin-4 in either OMAT or SCAT explants
(Table 1).
Inﬂammatory cytokines
Monocyte chemoattractant protein-1 (MCP-1) and tumour necro-
sis factor alpha (TNFα) are produced by both adipocytes and AT
resident macrophages and CD14 (cluster of differentiation 14) is a
monocyte/macrophage marker expression of which reﬂects
macrophage inﬁltration in AT.12 MCP-1 (also called CCL2; CC-
chemokine ligand 2) is involved in immune cell recruitment into
AT. Its expression was not signiﬁcantly affected by increasing
doses of Exendin-4 in either OMAT, or SCAT. We conﬁrmed this
observation by analysis of its protein secretion in the explant
media and found no change (data not shown). Similarly, we did
Figure 1. Exendin-4 stimulated adiponectin expression in OMAT explants. (a) Omental (OMAT) AT’s adiponectin mRNA expression as result of
increasing doses of Exendin-4 (0–100 nM). (b). Adiponectin concentrations in supernatant obtained from culture of OMAT and subcutaneous
adipose tissue (SCAT) explants with Exendin-4. *Po0.05, OMAT, n= 6; SCAT, n= 7.
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not ﬁnd any changes in TNFA or CD14 expression in response to
Exendin-4 (see Table 1). We also did not ﬁnd any modiﬁcation in
the expression of inﬂammatory markers after treatment with
Insulin with or without Exendin-4 (data not shown).
Fibrosis: ECM and its regulators
In order to assess Exendin-4’s impact on AT’s ECM composition,
we analysed expression of ECM main proteins (collagens,
ﬁbronectin and elastin), enzymes involved in their cross-linking
(LOX, lysosyl oxidase and LOXL2, lysyl oxidase-like 2) and
degradation (MMPs, metalloproteinases) as well as regulators of
ECM remodelling (TGFβ1, transforming growth factor beta 1 and
CTGF, connective tissue growth factor). We analysed expression of
the three main collagen types found in AT: COL1A1 (collagen 1
alpha subunit 1), COL3A1 (collagen 3 alpha subunit 1) and the
pericellular COL4A1 (collagen 4 alpha subunit 1).9 We did not ﬁnd
any signiﬁcant changes in the expression of these collagen
subunits in OMAT or SCAT (Table 1). Similarly, ﬁbronectin (FN1) did
not appear to be affected by Exendin-4 treatment. In contrast to
the collagens, elastin ﬁbres provide stretchiness to AT.3 We found
that Exendin-4 treatment signiﬁcantly decreased elastin (ELN)
expression within OMAT explants, however, this effect was not
seen within SCAT. We therefore assessed elastin synthesis by
measuring its release in culture media obtained from AT explants
treated with Exendin-4. Exposure of AT explants to high dose of
Exendin-4 signiﬁcantly decreased elastin synthesis in OMAT
explants but not SCAT (Figure 2b).
LOX and LOXL2 are two enzymes involved in collagen and
elastin cross-linking.13 We found that neither LOX nor LOXL2
responded to Exendin-4. Similarly, we observed no change on
expression of two key enzymes involved in ECM break down:
MMP9 and MMP14. Moreover in response to Exendin-4 treatment,
we monitored no change in the two pro-ﬁbrotic messengers:
TGFB1 and CTGF (Table 1).
Other proteins relevant to AT function
We assessed the expression of PPARG (peroxisome proliferator-
activated receptor gamma), one of the main regulator of
adipogenesis and did not observe any modiﬁcation, nor did we
ﬁnd a change in the hypoxia marker HIF1A (hypoxia inducible
factor 1 alpha) with hypoxia being one of the mediators of ﬁbrosis
and inﬂammation.14 Also, there were no changes in the
lipogenesis regulator LPL (lipoprotein lipase) or the endothelial
factor CD31 (cluster of differentiation 31)/PECAM1 (platelet/
endothelial cell adhesion molecule 1, see Table 1).
GLP-1R expression in OMAT and SCAT
Owing to the marked differences in the depot response to Exendin-
4 of both adiponectin and elastin, we further examined whether this
could be due to a difference in receptor expression. Using a cohort
of paired OMAT and SCAT samples (n=8), we observed, by western
blot, a stronger accumulation of GLP-1R in SCAT (Figure 3).
DISCUSSION
We examined direct effects of GLP-1 analogues on abdominal AT
depots, which are prone to expand with increasing obesity and
susceptible to AT dysfunction.15 Our study shows that acute
treatments based on GLP-1 analogues may have an advantage by
Table 1. Gene expression changes in adipose tissue explants following treatment with Exendin-4
Exendin-4 OMAT SCAT
1 nM 10 nM 100 nM P-value 1 nM 10 nM 100 nM P-value
Adipokines
ADIPOQ 0.89± 0.08 1.01± 0.09 1.13± 0.07 0.02 1.01± 0.06 1.05± 0.04 1.05± 0.05 0.69
LEP 1.00± 0.12 1.09± 0.10 1.00± 0.17 0.84 0.89± 0.09 0.93± 0.05 0.99± 0.08 0.32
Inﬂammation
CD14 0.91± 0.09 1.08± 0.11 0.97± 0.09 0.32 1.03± 0.07 1.00± 0.06 0.94± 0.09 0.42
MCP-1 0.97± 0.06 0.97± 0.07 0.93± 0.08 1.00 0.86± 0.10 0.86± 0.09 0.93± 0.09 0.48
TNFA 0.96± 0.07 1.11± 0.15 0.98± 0.12 0.77 0.96± 0.06 0.91± 0.06 1.03± 0.04 0.48
ECM and its regulators
COL1A1 1.00± 0.10 0.94± 0.05 0.91± 0.09 0.54 0.97± 0.09 1.02± 0.06 0.98± 0.08 0.86
COL3A1 0.92± 0.07 0.95± 0.07 0.91± 0.08 0.43 0.99± 0.08 1.06± 0.07 1.02± 0.05 0.42
COL4A1 0.95± 0.08 0.99± 0.10 1.01± 0.10 0.87 1.02± 0.08 1.07± 0.04 1.03± 0.06 0.61
CTGF 1.05± 0.15 0.92± 0.13 1.00± 0.17 0.16 0.93± 0.05 0.92± 0.07 1.01± 0.06 0.54
ELN 0.96± 0.07 0.84± 0.06 0.87± 0.11 0.03 0.95± 0.07 0.92± 0.06 0.98± 0.11 0.86
FN1 1.04± 0.09 0.95± 0.10 1.06± 0.09 0.32 0.94± 0.11 0.87± 0.06 0.86± 0.06 0.18
LOX 0.95± 0.08 0.93± 0.07 0.84± 0.04 0.16 0.96± 0.05 0.97± 0.05 0.95± 0.05 0.86
LOXL2 0.91± 0.09 0.90± 0.11 0.97± 0.07 0.94 0.98± 0.04 1.03± 0.02 1.02± 0.05 0.61
MMP9 1.09± 0.13 0.92± 0.15 0.77± 0.09 0.09 1.01± 0.19 0.91± 0.07 0.98± 0.08 0.82
MMP14 0.98± 0.09 0.97± 0.05 0.91± 0.06 0.67 0.98± 0.06 0.94± 0.06 0.97± 0.08 0.86
TGFB1 0.95± 0.09 0.93± 0.07 0.92± 0.04 0.57 0.95± 0.05 0.95± 0.05 0.96± 0.08 0.86
Others
CD31 0.85± 0.08 0.88± 0.10 0.94± 0.07 0.77 1.01± 0.08 0.99± 0.04 0.99± 0.05 0.93
HIF1A 0.93± 0.07 0.92± 0.06 0.90± 0.06 0.26 0.98± 0.03 0.90± 0.06 0.96± 0.05 0.12
LPL 0.93± 0.06 1.05± 0.06 1.04± 0.08 0.38 1.04± 0.04 0.98± 0.02 1.06± 0.04 0.09
PPARG 0.91± 0.06 1.04± 0.11 1.05± 0.08 0.51 1.02± 0.07 1.03± 0.05 1.06± 0.07 0.82
Abbreviations: ECM, extracellular matrix; OMAT, omental; SCAT, subcutaneous adipose tissue. Expression of genes in human OMAT (n= 6) and SCAT (n= 7)
explants treated 45 h with increasing doses of Exendin-4. Data were normalised to the control condition and expressed as the mean± s.e.m. Signiﬁcant
P-values are in bold.
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increasing adiponectin expression and that they reduce elastin
secretion by which they take part in ECM remodelling. Studying
whole AT, with its stromal vascular fraction, enables to account for
the cross-talk between its different cell populations. Preadipocytes
and adipocytes both express GLP-1R6 and are involved in ECM
protein production. This model allowed us for the ﬁrst time to
study effects of GLP-1 on the ECM without the inﬂuence of weight
loss or glycaemic improvement which are recognized effects of
GLP-1 analogue treatments.
GLP-1 and adiponectin
In response to Exendin-4, we found a dose-dependent increase of
adiponectin expression in OMAT explants. Adiponectin is, mainly
secreted by adipocytes, with plasma concentrations inversely
correlated with insulin resistance, type-2 diabetes and obesity.11
Adiponectin has insulin-sensitising and anti-inﬂammatory proper-
ties and an ability to enhance pancreatic β-cells regeneration.16
Though adiponectin is mainly secreted by SCAT, Drolet et al.17
found that the OMAT release of adiponectin was reduced with
increasing BMI, total body fat mass and visceral AT area,
suggesting that OMAT could be responsible for the hypoadipo-
nectinemia associated with obesity. Treatments of patients with
GLP-1R agonists promote weight loss and increase circulating
adiponectin levels.18 However, little is so far known about GLP-1
treatment effects on human AT in vivo controlled for weight
change, apart from a recent study in which Exenatide was started
in type-2 diabetic subjects prior to bariatric surgery. This study has
shown similar to us, a selectively increase of adiponectin
expression in visceral not SCAT.19 In line with these ﬁndings, our
results go further and show that Exendin-4 treatment changes
adiponectin expression in OMAT has yet little effect on
adiponectin secretion. Thus, the increased circulating adiponectin
secretion as previously reported with GLP-1 treatment is mainly a
feature of weight loss.20 An accumulative effect, stronger with
chronic treatment, cannot be excluded. Murine studies postulate
activation of a PKA-dependent pathway21 and M2 macrophage
polarisation22 as potential pathways by which GLP-1 may
stimulate adiponectin expression.
GLP-1 and ECM
Weight loss is accompanied by profound ECM remodelling. In vitro
studies allow assessment of GLP-1 effects independent of weight
loss. We showed a decrease of elastin expression in OMAT in
response to Exendin-4, whereas ﬁbre forming type I, II and IV
collagens did not appear to be affected. Elastin confers resilience,
elasticity and deformability to many connective tissues including
AT.3 Elastin was reported to be less abundant in AT from non-
diabetic obese than lean subjects when assessed by
immunohistology.23 Furthermore, mice with haplo-insufﬁciency
of the elastin gene in a ApoE−/− background had impaired
glucose metabolism and demonstrated adipocyte hypertrophy,24
supporting that elastin production is impaired in obesity and that
it may have a role in glucose metabolism. The signiﬁcance of the
Exendin-4 induced decrease of elastin expression and secretion on
AT function needs yet to be further clariﬁed. Mechanical proper-
ties of ECM result from a balance between relative abundance of
elastin and collagen, their efﬁcient cross-linking by LOX and
LOXL2 and their degradation, which is inﬂuenced by metallopro-
teinases and their inhibitors. Apart from the change in elastin, we
did not observe any modiﬁcation of LOX, LOXL2 or MMPs
expression in response to Exendin-4 treatment, and cannot
conclude an effect of GLP-1 to histological changes or mechanical
properties of AT’s ECM, as technically not feasible. Similarly, the
expression of TGFB1 and its downstream target CTGF, two key pro-
ﬁbrotic factors were not affected by Exendin-4, suggesting that
GLP-1 does not induce a pro-ﬁbrotic phenotype, though a change
in the mechanical property by changing the ratio of collagen/
elastin3 cannot be excluded.
GLP-1 and inﬂammation
Chronic low-grade inﬂammation and macrophage inﬁltration in
AT have been reported to be closely related to the development
of obesity and insulin resistance.25 We analysed the expression of
inﬂammation markers in response to Exendin-4 treatment and
found no change in either abdominal depot. Most importantly, we
did not ﬁnd changes in MCP-1 expression or secretion, whereas
some studies suggest that 12 weeks treatment of obese patients
with type-2 diabetes with the GLP-1R agonists, Exenatide
decreases circulating cytokines including MCP-1 plasma concen-
trations independent of weight change, however, with a
signiﬁcant improvement in glycaemia.26 Other reports show that
GLP-1 analogues inhibit expression of inﬂammatory cytokines in
3T3-L1 adipocytes.21 Nevertheless, anti-inﬂammatory properties of
GLP-1 analogues have not been conﬁrmed as direct effect and
speciﬁc to human AT and several groups have seen no
modiﬁcation in MCP-1 or other cytokines’ plasma concentrations
(which are likely to be attributable to AT inﬂammation) in non-
obese subjects with type-2 diabetes despite weight loss,18 nor a
change in AT expression of TNFα or MCP-1 in non-diabetic rats
treated with Exenatide.27 An obvious direct effect of GLP-1 on AT
inﬂammation independent of weight loss effects thus remains
questionable. Clinical studies controlling for the improvement in
glycaemia and the effect of weight loss, for example, by
Figure 2. Exendin-4 treatment decreased expression and secretion of elastin in OMAT. (a) Accumulation of elastin mRNA in OMAT after
treatment with 0, 1, 10, 100 nM of Exendin-4 (OMAT, n= 6; SCAT, n= 7). (b) Elastin release into media of OMAT and SCAT in response to
Exendin-4 treatments and signiﬁcant for comparison of 0 nM vs 100 nM (OMAT, n= 9; SCAT, n= 7). *Po0.05.
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comparing patients with dietary induced weight loss of similar
magnitude to the GLP-1 induced weight loss are needed.
Differential AT depot response
We found only OMAT responsive to Exendin-4 treatment. OMAT
and abdominal SCAT exhibit different patterns of gene
expression,28 OMAT has higher lipolytic activity15 and has as part
of visceral AT a clear link with the development of metabolic
syndrome characteristics (including glucose intolerance, hyper-
insulinemia and hypertriglyceridemia) and cardiovascular
disease.15 We postulated that the difference between OMAT and
SCAT response could have been due to a differential expression of
GLP-1R. We found more GPL1-R protein in SCAT, demonstrating
that the different response to Exendin-4 is unlikely explained by
the amount of GLP-1R. Higher expression of GLP-1R was found in
OMAT of obese insulin-resistant subjects when compared with
subjects with low insulin resistance,6 however, we were not able
to reproduce these ﬁndings in morbidly obese subjects of whom
most had diabetes. GLP-1R resistance in combination with insulin
resistance cannot be excluded.
We acknowledge some study limitations. We may have missed
peaks in mRNA expression occurring prior to 45 h of tissue culture
and/or later mRNA changes. The duration was in part chosen to
enable the study of cytokine and protein accumulation in the media.
Similar to other in vitro studies,6,7 we used 1–100 nM of Exendin-4 in
our experiments. Even if previous pharmacokinetic studies showed
that Exendin-4 treatment with current dosing results in circulating
levels between 2.5 and 5 nM,29 higher doses of GLP-1 analogues are
now under consideration for weight management.2 AT samples were
used from non-diabetic overweight/obese subjects who are typically
insulin resistant, whereas GLP-1 treatment is primarily for subjects
with type-2 diabetes. We have expected an improvement in AT
inﬂammation as reported in rodents and humans (circulatory/plasma
inﬂammatory markers),26,30 which we were unable to conﬁrm and did
not expect the need to stimulate inﬂammation in this in vitro explant
model. Further studies are necessary, which include a model to take
account of macrophage inﬁltration and polarisation within explant
culture. We used normoglycaemic conditions as will be achieved by
effective treatment of diabetes with GLP-1 analogues or when used in
non-diabetic subjects for weight management. Furthermore, we were
only able to study acute effects and can only hypothesise that they
may become more pronounced with prolonged treatment.
In summary, Exendin-4 can directly modify expression of
adiponectin and elastin in explant culture of human AT.
Interestingly, OMAT, expansion of which is linked to the
development of insulin resistance and the metabolic syndrome,
seems to be more sensitive to Exendin-4, despite higher GLP-1
receptor expression in subcutaneous tissue. These results suggest
that treatment of patients with type-2 diabetes and/or obesity
with GLP-1 analogues could directly inﬂuence AT physiology, its
properties and functions. However, apart from the positive effect
on increased adiponectin expression/secretion we cannot verify
an anti-inﬂammatory effect of GLP-1 on AT independent of
weight loss.
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